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Abstract
Background Negative symptoms are the core of schizophrenia, but whether antipsychotics are efficacious for their 
treat-ment is unclear. Moreover, there is debate whether patients in relevant trials should have predominant negative 
symptoms or whether prominent negative symptoms are also acceptable.
Methods We systematically reviewed randomised, blinded antipsychotic drug trials in patients with schizophrenia and 
either predominant or prominent negative symptoms (last search Dec 12, 2017). Separate pairwise meta-analyses were 
conducted in these two populations. The primary outcome was negative symptoms. Depressive, symptoms, positive 
symptoms, and extrapyramidal side-effects were analysed as causes of secondary negative symptoms.
Findings We included 21 randomized-controlled trials with 3451 participants which revealed the following significant 
differences in the primary outcome: in patients with predominant negative symptoms amisulpride was superior to placebo 
(N = 4; n = 590, SMD 0.47, CI 0.23, 0.71), olanzapine was superior to haloperidol in a small trial (n = 35) and 
cariprazine outperformed risperidone (N = 1, n = 456, SMD − 0.29, CI − 0.48, − 0.11). In patients with prominent 
negative symptoms, olanzapine and quetiapine were superior to risperidone in single trials. Overall, studies in prominent 
negative symptoms were potentially more confounded by improvements of secondary negative symptoms.
Interpretation Amisulpride is the only antipsychotic that outperformed placebo in the treatment of predominant 
negative symptoms, but there was a parallel reduction of depression. Cariprazine was better than risperidone in a large 
trial that was well-controlled for secondary negative symptoms, but the trial was sponsored by its manufacturer. Future 
trials should apply scientifically developed definitions such as the deficit syndrome and the persistent negative symptoms 
concept.
Keywords Deficit syndrome · Deficit schizophrenia · Persistent negative symptoms · Depressive symptoms · Positive 
symptoms · Study design
Introduction
Eugen Bleuler described negative symptoms in schizo-
phrenia as the core of the disorder. There have been multi-
ple efforts to further conceptualize these symptoms, [1–6] 
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such as the type I, type II concept by Crow [3], or the 
concept by Andreasen and Olsen [5] that distinguishes 
between positive, negative, and mixed-subtype symptoms 
of schizophrenia. An elaborate and well-evaluated concept 
is the deficit syndrome developed by Carpenter et al. [2] 
and Buchanan et al. [1]. Their definition comprises at least 
two of five pre-defined negative symptoms, which are not 
the cause(s) of depression, anxiety, drug effects or envi-
ronmental deprivation, as well as symptoms persisting for 
at least 12 months [2]. Moreover, in 2007, Buchanan [7] 
presented the broader concept of persistent negative symp-
toms which requires at least moderate negative symptoms, 
a defined threshold of positive symptoms, and no or low 
depressives and extrapyramidal symptoms (all defined on 
validated scales), with demonstrated clinical stability.
Antipsychotic drugs, the mainstay of treatment for 
schizophrenia, have been shown to be effective for nega-
tive symptoms, but it is unclear whether they only improve 
so-called ‘secondary’ or also ‘primary’ negative symptoms 
[8]. For example, meta-analyses showed that second-gen-
eration antipsychotics and haloperidol reduced negative 
symptoms more than placebo [9]. However, almost all 
included studies focused on patients with exacerbations 
of positive symptoms. In such studies, it is possible that 
improvements of negative symptoms are only second-
ary to reductions of positive symptoms. Similarly, some 
second-generation antipsychotics were more efficacious 
than first-generation antipsychotics in another meta-anal-
ysis [10], but these effects might have been due in part to 
the extrapyramidal side-effects of haloperidol which can 
mimic negative symptoms.
Therefore, studies in specific populations are needed to 
determine whether antipsychotic drugs are truly effective for 
primary negative symptoms. In this context, there is a dis-
cussion whether it is sufficient that patients have ‘prominent’ 
negative symptoms or whether negative symptoms should 
also be ‘predominant.’ While patients with prominent nega-
tive symptoms are characterized only as patients with a high 
degree of negative symptoms, the definition of predominant 
negative symptoms includes the additional criteria of no-to-
little positive symptoms [11]. While the European Medical 
Agency (EMA) requires predominant negative symptoms 
in such studies, the United States Food and Drug Agency 
(FDA) is somewhat less stringent in this regard, and an inter-
national expert consensus conference with participants from 
academia, industry and the EMA did not find an agreement 
[11].
We, therefore, conducted a systematic review on the 
effects of antipsychotics in patients with negative symp-
toms as inclusion criteria. The aims were to determine 
which antipsychotics are more efficacious than placebo, and 
whether there are differences between single antipsychot-
ics. Moreover, we evaluated whether studies in prominent 
or 
in predominant negative symptom studies could have been 
more confounded by secondary negative symptoms.
Methods
An a priori written study protocol was registered at PROS-
PERO under the registration number: CRD42016052060.
Participants and interventions
We included all randomized controlled trials (RCTs) in 
patients with schizophrenia, schizophreniform disorder, or 
schizoaffective disorder (as defined by any diagnostic cri-
teria) which focussed on patients with negative symptoms 
according to their in- and exclusion criteria. This means 
that we excluded studies in which it was described only 
in the introduction or discussion sections that patients had 
primarily negative symptoms. We then classified the stud-
ies into “predominant” and “prominent” negative symptom 
studies. As there are no uniformly accepted criteria for this 
distinction, we followed the broad conceptualisation of the 
international consensus conference published by Marder 
et al. [11] (see point 3.2 there). According to this report, 
predominant negative symptoms can occur in the presence 
of other symptoms, in particular psychotic symptoms, but 
these are only relatively mild and well controlled [11]. For 
prominent negative symptoms, however, it is not necessary 
that the level of psychotic symptoms is low at the same time 
as negative symptoms are high [11]. Thus, definitions that 
were eligible for inclusion in the prominent subgroup had 
to entail that the patients experienced a considerable degree 
of negative symptoms regardless of the degree of positive 
symptoms. Definitions that were eligible for the predominant 
subgroup had to assure that the patients had more negative 
symptoms than positive symptoms. In addition, the level of 
positive symptoms had to be low. Moreover, the minimally 
necessary degree of negative symptoms and the maximally 
possible degree of positive symptoms had to be operation-
alised by scale-derived criteria. As the exact cutoffs varied 
(see “Discussion”), further refinement was not possible (see 
“Discussion”).
As we wanted to address whether studies in prominent 
negative symptoms may be more confounded by positive 
(and other) symptoms than studies conducted in patients 
with predominant negative symptoms, the subgroups were 
examined in two separate meta-analyses.
The interventions were 34 antipsychotic drugs which 
comprised all second-generation antipsychotics available 
in the US and/or Europe, and a selection of first-genera-
tion antipsychotics, licensed in at least one country, which 
were considered important based on a survey of interna-
tional schizophrenia experts [12] (amisulpride, aripiprazole, 
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asenapine, benperidol, brexpiprazole, cariprazine, chlor-
promazine, clopenthixol, clozapine, flupenthixol, flu-
phenazine, fluspirilene, haloperidol, iloperidone, levome-
promazine, loxapine, lurasidone, molindone, olanzapine, 
paliperidone, penfluridol, perazine, perphenazine, pimozide, 
quetiapine, risperidone, sertindole, sulpiride, thioridazine, 
thiothixene, trifluoperazine, ziprasidone, zotepine, and 
zuclopenthixol). We included these drugs at any dose and 
in any form of administration when compared with another 
antipsychotic or placebo, and used as monotherapy. Drugs 
that failed to obtain FDA/EMA approval or which have not 
been licensed yet were not considered.
Search strategy and selection criteria
We conducted a comprehensive, systematic literature search 
in MEDLINE, EMBASE, PsycINFO, Cochrane Library, 
PubMed, Biosis, and ClinicalTrials.gov up to Nov 17, 2016 
(eAppendix 2 in the Supplement) and a final PubMed search 
until Dec 12, 2017. The search terms included the generic 
names of 34 antipsychotics listed above. The minimum dura-
tion of the RCTs was set at 3 weeks. We also inspected the 
reference lists of the included studies and of the previous 
systematic reviews [13, 14] and a narrative review [15] about 
negative symptoms. Citations were screened independently 
by at least two reviewers (MK, MH, YZ) at both the title/
abstract and full-text stages. In the case of crossover studies, 
we only used the first crossover phase to avoid the problem 
of carryover effects [16]. We excluded cluster-randomized 
trials [17]. Studies that demonstrated a high risk for bias 
for sequence generation or allocation concealment were 
excluded [18]. If a trial was described as double blind, but 
randomization was not explicitly mentioned, we assumed 
that study participants were randomized, and we excluded 
the trial in a sensitivity analysis. We excluded studies from 
mainland China to avoid a systematic bias, because many of 
these studies do not use appropriate randomization proce-
dures, but as their methods usually presented only briefly, it 
is difficult to evaluate them [19, 20].
Outcome measures and data extraction
The primary outcome was the mean change from base-
line to endpoint in negative symptoms of schizophrenia as 
measured by negative subscales of the Positive and Nega-
tive Syndrome Scale [14, 21] (PANSS-negative), the Scale 
for the Assessment of Negative Symptoms [22] (SANS), 
or any other validated scale for the assessment of nega-
tive symptoms in schizophrenic patients such as the Brief 
Negative Symptom Scale [23] (BNSS). If change data were 
not available, we used the mean score at study endpoint of 
these scales. Intention-to-treat data sets were used whenever 
available.
Secondary outcomes were depressive and positive symp-
toms (change from baseline to endpoint or at endpoint) as 
measured by published rating scales, the number of patients 
receiving antiparkinson medication at least once, and the 
number of patients who experienced at least one extrapy-
ramidal side-effect. These outcomes were examined to find 
out whether effects on negative symptoms might have been 
confounded by secondary negative symptoms. Other side-
effect data were extracted, but not analysed, because there 
is no reason to believe that they differ from those in patients 
with exacerbations of positive symptoms for whom many 
more data were available [24]. Moreover, few side-effect 
data were available, so that these results would have con-
tributed little.
We used the Cochrane Collaboration’s risk-of-bias tool 
for the assessment of potential bias in terms of randomisa-
tion, allocation concealment, blinding, missing outcomes, 
selective reporting, and other biases [18].
Data extraction and assessment of study quality were 
performed independently by at least two reviewers (MK, 
YZ, MH, JS, IB, SL, and PR). We sent emails to the first 
and corresponding authors of all included studies to request 
missing data. Missing SDs were estimated from test statistics 
or substituted by the mean SD of the other included studies 
using the same scale [25].
Statistical analysis
We originally planned to conduct a network meta-analysis. 
However, there were only a few eligible studies; thus, the 
network plot was very poorly connected (see Fig. 1). The 
design-by-treatment interaction model [26, 27] showed a 
high degree of statistical inconsistency for the primary out-
come  (chi2 (1) = 5.89 and p value > chi2 = 0.0153). Therefore, 
we decided to calculate pairwise, random-effects meta-anal-
yses. Moreover, as we aimed to compare studies in predomi-
nant and prominent negative symptoms, this approach was 
more appropriate, because results of individual studies can-
not be visualised in network meta-analysis. For continuous 
outcomes, the effect sizes were calculated as standardized 
mean differences (SMDs) according to Hedges’s g [18]. For 
binary outcomes, the effect sizes were calculated as odds 
ratios (ORs). Both types of effect sizes were presented along 
with their 95% confidence intervals (CIs). We applied the 
random-effects model by Der-Simonian and Laird [28] to 
all outcomes. Heterogeneity was assessed with the I2 statis-
tic [18] and a  chi2-square test for homogeneity. Small trial 
effects were explored by funnel-plots if at least ten studies 
were available [18]. As the method is based on symmetry, 
funnel plots based on fewer trials are not meaningful [18]. 
The network plots and the analysis of inconsistency were 
made with the network graphs package in Stata 14 [29]. 
All other statistical calculations were made with RevMan 
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version 5.3 [30], p values lower than 0.05 were considered 
to be statistically significant.
Results
Description of included studies
We identified 43 references from 21 [31–50] unique RCTs 
with 3451 unique participants published from 1989 to 2017. 
The PRISMA flowchart is shown in eFigure 1. Of the 15 
excluded studies, four studies may be noteworthy, because 
they somehow described their patients as having mainly 
negative symptoms in the “Introduction” or “Discussion” 
[51–54]. However, as negative symptoms were not defined 
by inclusion/exclusion criteria, these studies were excluded 
(see eAppendix 3). Details of all included studies are pre-
sented in Table 1. Of 3352 patients with gender indicated, 
2245 were men (67%). The mean age of participants was 39 
and 83 years. The median trial duration was 12 weeks (range 
6–52 weeks). The assessment for risk of bias is presented in 
eAppendix 4 in the Supplement. The trial reports often did 
not provide clear details about randomization procedures 
(> 50%) and allocation concealment (60%). The blinding 
of patients and personnel was unclear in 30% of the studies 
and showed a high risk for unsufficient blinding (10%). The 
risk of bias for blinding of outcome assessment was similar 
with 30% unclear and 5% high risk. The rates of high risk of 
bias for missing outcomes and selective reporting were 20 
and 50%, respectively.
Figure 1 shows the network of eligible comparisons for 
the primary outcome. The identified studies included the 
drugs amisulpride, sulpiride, asenapine, cariprazine, clo-
zapine, flupentixol, fluphenazine, haloperidol, olanzapine, 
placebo, quetiapine, risperidone, ziprasidone, and zotepine. 
Nine of the 21 included studies met our criteria for patients 
with predominant negative symptoms and included the treat-
ments (one study [34] had three arms): amisulpride (N = 4), 
asenapine (N = 2), cariprazine (N = 1), haloperidol (N = 1), 
olanzapine (N = 4), placebo (N = 5), risperidone (N = 1), and 
zotepine (N = 1). The other 12 studies included patients with 
schizophrenia and prominent negative symptoms and inves-
tigated the following drugs: amisulpride (N = 4), sulpiride 
(N = 1) clozapine (N = 1), flupentixol (N = 1) fluphenazine 
(N = 2), haloperidol (N = 2), olanzapine (N = 3), quetiapine 
(N = 3), risperidone (N = 3), sulpiride (N = 1), ziprasidone 
(N = 1), zotepine (N = 1).
Outcome results
One aim of our systematic review was to judge qualitatively 
whether reduction of negative symptoms may be secondary 
to effects on depressive symptoms or positive symptoms. To 
facilitate this judgement, the results of these three outcomes 
are presented in parallel in panel figures (Figs. 2, 3). Figure 2 
summarizes the main results for the predominant negative 
symptom subgroup, Fig. 3 those of the prominent negative 
symptom subgroup. eFigures 5 and 6 present results on “use 
of antiparkinson medication at least once” for patients with 
predominant negative symptoms, respectively, prominent 
negative symptoms, and eFigure 7 and eFigure 8 present the 
same for the outcome “at least one extrapyramidal symptom 
(EPS).”
Fig. 1  Network plots for mean change in negative symptoms of schiz-
ophrenia. The size of the nodes corresponds to the number of trials 
that study the treatments. Directly comparable treatments are linked 
with a line. The number of studies and comparisons can be different, 
because of multiple-arm studies. a Network plot for the subgroup of 
patients with predominant negative symptoms. b Network plot for the 
subgroup of patients with prominent negative symptoms. N Number 
of studies, n number of participants. Ami amisulpride, Ase asenapine, 
Cari cariprazine, Cloz clozapine, Flup flupentixol, Fluph fluphena-
zine, Hal haloperidol, Ola olanzapine, Pla placebo, Quet quetiapine, 
Ris risperidone, Zip Ziprasidone, Zot zotepine
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Patients with predominant negative symptoms: 
effects on psychopathology
Three drugs were compared with placebo (see Fig. 2). For 
amisulpride, four placebo-controlled trials were available. 
Amisulpride was significantly better than placebo for nega-
tive symptoms (N = 4; n = 590, SMD 0.47, CI 0.23, 0.71) 
and depression (N = 4, n = 345, SMD 0.35, CI 0.02, 0.68), 
while the effect size for positive symptoms was not signifi-
cant (see Fig. 2). Based on a single trial, olanzapine was 
not significantly more efficacious than placebo in neither 
negative symptoms, nor depression nor positive symptoms, 
and again, based on a single study, zotepine outperformed 
placebo only in depressive symptoms (N = 1, n = 79, SMD 
0.48, CI 0.03 to 0.93).
In terms of direct comparisons between antipsychotics, 
there were no significant differences between amisulpride 
and olanzapine, and between asenapine and olanzapine, 
except that asenapine was inferior compared to olanzap-
ine for positive symptoms. Olanzapine was significantly 
better than haloperidol for negative symptoms in a small 
trial (N = 1, n = 35, SMD 0.75, CI 0.06–1.44); the SMDs 
for depression and positive symptoms were not statistically 
significant. The largest trial (n = 456) found a significant 
superiority of cariprazine compared to risperidone (N = 1, 
n = 456, SMD − 0.29, CI − 0.48 to − 0.11). In this compari-
son, there were virtually no differences between drugs in 
terms of depressive and positive symptoms (see Fig. 2).
Patients with prominent negative symptoms: effects 
on psychopathology
There were no placebo-controlled studies for this subgroup 
except one study in which sulpiride tended to be less effica-
cious (see Fig. 3). In terms of direct comparisons between 
antipsychotics, there was no significant difference in nega-
tive symptoms between amisulpride versus fluphenazine, 
amisulpride versus haloperidol, and amisulpride versus 
ziprasidone. In all three comparisons, only one study [43] 
provided useable data for another outcome—depressive 
symptoms—where amisulpride was significantly superior 
to fluphenazine (N = 1, n = 48, SMD − 0.78, CI − 1.37 to 
− 0.19).
There was no significant difference between risperidone
and flupenthixol in terms of negative symptoms, positive 
symptoms, and depressive symptoms. A single study showed 
a superiority of olanzapine compared to risperidone in terms 
of both negative symptoms (N = 1, n = 235, SMD − 0.30, 
Fig. 2  Forest plots of pairwise meta-analyses for patients with pre-
dominant negative symptoms. The size of squares reflects the weight 
attributed to each study for every separate pairwise meta-analysis (per 
comparison). Error bars indicate 95% CI. A standardized mean dif-
ference smaller than zero means that the first mentioned drug is bet-
ter for the reduction of specific symptoms. a negative symptoms, b 
depressive symptoms, and c positive symptoms. ‘Not estimable’ 
means that there were no useable data for this outcome
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CI − 0.04 to − 0.56) and positive symptoms (N = 1, n = 235, 
SMD − 0.32, CI − 0.06 to − 0.57).
While there was no significant difference between olan-
zapine and quetiapine for the reduction of negative and 
depressive symptoms, olanzapine was significantly better 
for the treatment of positive symptoms (N = 2, n = 376, SMD 
− 0.29, CI − 0.49 to − 0.09).
In a small single study, quetiapine was superior compared
to risperidone in the treatment of negative symptoms (N = 1, 
n = 44, SMD − 1.34, CI − 2.00 to − 0.68), while the effect 
size for positive symptoms was significant in the opposite 
direction (N = 1, n = 44, SMD 0.63, CI 0.02–1.23).
One study comparing clozapine with haloperidol did not 
show a difference in terms of negative and positive symp-
toms (see Fig. 3).
Use of antiparkinson medication and at least one 
extrapyramidal side‑effect
In studies on patients with predominant negative symp-
toms, use of antiparkinson medication at least once was 
only reported for the comparisons between amisulpride 
and placebo and for asenapine versus olanzapine. In neither 
analysis, there was a significant difference (see eFigure 5).
In studies on prominent negative symptoms, significantly, 
more fluphenazine-treated patients received antiparkinson 
medication frequently than did those on amisulpride (N = 1, 
n = 102, OR 0.11 CI 0.01–1.01), flupenthixol-treated patients 
received it more frequently than those on risperidone (N = 1, 
n = 153, OR 2.80 CI 1.40–5.60), and risperidone-treated 
patients more frequently than those on quetiapine (N = 1, 
n = 44, OR 0.14 CI 0.03–0.78). The other results were not 
statistically significant, but the trend was always to the 
disadvantage of the more dopaminergic compounds (see 
eFigure 6).
Very few studies reported the outcome “at least one 
extrapyramidal side effect”. The effects were compara-
ble to use of at least one antiparkinson medication. The 
only relevant additional information was that in a single 
study of patients with prominent negative symptoms, ris-
peridone produced significantly more EPS than olanzapine 
(N = 1, n = 246, OR 2.50, CI 1.48–4.24, see supplemental 
eFigure 8).
Assessment of heterogeneity and small trial bias
We did not detect significant heterogeneity in any outcome. 
As there were very few studies for most of the comparisons, 
heterogeneity might not be well estimated. Funnel plots 
Fig. 3  Forest plots of pairwise meta-analyses for patients with promi-
nent negative symptoms. The size of squares reflects the weight 
attributed to each study for every separate pairwise meta-analysis 
(per comparison). Error bars indicate 95% CI. A standardized mean 
difference smaller than zero means that the first mentioned drug is 
better for the reduction of specific symptoms. a negative symptoms, 
b depressive symptoms, and c positive symptoms. ‘Not estimable’ 
means that there were no useable data for this outcome
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to detect small trial/publication bias were not meaningful, 
because the maximum number of trials available for a com-
parison was four, not enough to decide on asymmetry of 
the plots.
Discussion
To the best of our knowledge, this is the first systematic 
review and meta-analysis regarding the effects of antipsy-
chotics in people with schizophrenia and negative symptoms 
as inclusion criteria. The main findings were that in terms of 
predominant negative symptoms, amisulpride was more effi-
cacious than placebo. Moreover, based on a large trial [38], 
cariprazine was superior to risperidone, and based on a small 
trial [35], olanzapine was superior to haloperidol. In terms 
of prominent negative symptoms, only olanzapine and que-
tiapine significantly outperformed risperidone, again, each 
based on a single study (247 [39] and 44 [44] participants, 
respectively). Possible confounding due to parallel effects 
on depression, positive symptoms or EPS occurred in many 
studies, albeit more frequently in prominent negative symp-
toms studies.
In patients with predominant negative symptoms, ami-
sulpride was the only antipsychotic that was significantly 
more efficacious than placebo. This result can be consid-
ered rather robust, because it was based on four studies with 
590 participants who is recommended. The effectiveness of 
amisulpride for negative symptoms is explained, since ami-
sulpride is a selective dopamine D2/D3 receptor antagonist. 
Previous studies have proposed that hypodopaminergic tone 
in prefrontal cortex may underlie some of the pathophysiol-
ogy of negative symptoms and that amisulpride which at low 
doses (here 50–300 mg/day) binds to presynaptic receptors 
in the frontal cortex may enhance dopamine transmission in 
this area. However, there was also a significant superiority 
of amisulpride for depressive symptoms. Indeed, it has been 
shown that amisulpride is also a 5-HT7 antagonist which 
can explain its antidepressant effects [55], and amisulpride 
has an official indication for dysthymia in some European 
countries [56]. As depressive and negative symptoms over-
lap, it is difficult to say whether amisulpride reduces primary 
or only secondary negative symptoms. Moreover, with the 
exception of the only negative study [34], all studies were 
conducted by the manufacturer of amisulpride. Actually, 17 
out of 21 included studies (81%) were sponsored by phar-
maceutical companies, see Table 1. In head-to-head com-
parisons of antipsychotics, there were only two statistically 
significant differences between compounds. The single study 
showing a superiority of olanzapine over haloperidol was 
relatively small (n = 35), so that a replication is needed [35]. 
The superiority of cariprazine compared to risperidone was 
more convincing [38]. The sample size was large (n = 461), 
there was a run-in phase confirming that negative symp-
toms were stable, and there was virtually no effect on either 
depressive symptoms or positive symptoms, and no differ-
ential effects on extrapyramidal side-effects (see Fig. 2 and 
the original publication [38]). Greater affinity to D3 than D2 
dopamine receptors in addition to preferential limbic action 
has been discussed as potential mechanisms of action [57]. 
However, this study was sponsored by the manufacturer of 
cariprazine and placebo-controlled evidence is lacking.
The problem in several studies of patients with promi-
nent negative symptoms was that the effect sizes for posi-
tive symptoms were either identical or higher than those 
for negative symptoms. This renders the possibility of con-
founding by secondary effects more likely. Concretely, in the 
comparisons of risperidone with flupenthixol, of olanzap-
ine with quetiapine, and of clozapine with haloperidol, only 
the SMDs for positive symptoms were significant and they 
were higher than those for negative symptoms (see Fig. 3). 
In the single study comparing olanzapine with risperidone, 
the effect sizes for negative and positive symptoms were 
virtually identical. The results of the single study comparing 
quetiapine with risperidone are difficult to interpret, because 
quetiapine was significantly better for negative symptoms, 
but less efficacious for positive symptoms. Perhaps, this can 
be explained in part by quetiapine being a norepinephrine 
reuptake inhibitor [58, 59] which is FDA-approved for the 
treatment of major depressive disorder [60]. However, sig-
nificant effects in opposite directions are unusual in antipsy-
chotic trials, and the study was relatively small. Amisulpride 
was not significantly better than fluphenazine for negative 
symptoms, but was for depression. Finally, in its only small 
study, sulpiride tended to be less efficacious than placebo, 
but this effect was due to the fact that negative symptoms 
were lower in the placebo group at baseline. When the origi-
nal authors corrected for this baseline imbalance, sulpiride 
was more efficacious than placebo [50], in contrast to what 
Fig. 3 suggests.
We believe that the results can be interpreted qualita-
tively in the sense that it is less stringent to evaluate negative 
symptoms in patients with prominent negative symptoms 
than in patients with predominant negative symptoms. In the 
former group, the effects are even more difficult to disentan-
gle from effects on other symptoms, in particular, positive 
symptoms. In three [39, 42, 47] of six studies measuring 
both negative and positive symptoms, the effect size for posi-
tive symptoms was equal or higher than that for negative 
symptoms (Fig. 3). In the subgroup, predominant negative 
symptoms, this was the case in only one study [37] (Fig. 2), 
although as discussed above, even many of these studies 
were not ideal.
Moreover, there was no overlap in the categories, and 
comparisons were either available for the predominant or 
the prominent subgroup (e.g., all amisulpride versus placebo 
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studies fell in the predominant subgroup). Thus, if we had 
not applied this distinction, the results for each drug would 
have been the same.
We did not examine differences between second-genera-
tion and first-generation antipsychotics as classes, because 
this classification has been replaced with “Neuroscience 
Based Nomenclature (NbN)” by societies such as the Euro-
pean and the American Colleges of Neuropsychopharmacol-
ogy [59]. However, the analysis of ‘antiparkinson medica-
tion use’ and ‘at least one EPS’ showed that it is difficult 
to compare compounds that produce many extrapyramidal 
side-effects (in particular, D2 receptor antagonists such as 
haloperidol, but also risperidone) with antipsychotics which 
are not very prone to extrapyramidal side-effects (e.g., 
D2/5-HT2 receptor antagonists and norepinephrine reup-
take inhibitors such as quetiapine [59]). Such comparisons 
often could be biased by the higher frequency of extrapy-
ramidal side-effects in the former group, mimicking negative 
symptoms (see eFigures 7 and 8). Prophylactic antiparkin-
son medication could mitigate the phenomenon, however, 
only Lindenmayer et al. [35] and Buchanan et al. [41] have 
applied this strategy.
How do these results mesh with what we know about the 
efficacy of other pharmacological treatments for negative 
symptoms? A comprehensive meta-analysis of 168 RCTs 
found significant effects on negative symptoms for antide-
pressants, second-generation antipsychotics, psychological 
treatments, glutamatergic medication, and the combination 
of pharmacological agents [14]. In an overview of reviews, 
12 out of 26 pharmacological cotreatments added to antip-
sychotics significantly outperformed controls [61]. However, 
in both reviews, the study populations were not restricted to 
patients with prominent/predominant negative symptoms. 
Thus, effects on secondary negative symptoms, again, 
could not be ruled out. A subgroup analysis of patients with 
predominant negative symptoms in a meta-analysis on the 
effects of antidepressants added to antipsychotics revealed 
a significant positive effect (N = 17, N = 729; SMD − 0.58, 
CI − 0.94 to − 0.21) [62]. Therefore, the addition of antide-
pressants to antipsychotics is an evidence-based treatment 
for negative symptoms in schizophrenia, [63] with the caveat 
that the inclusion criteria of these studies were not as strin-
gent as in the current review. All definitions of the original 
authors were accepted without further operationalisation in 
this previous systematic review [63].
The present meta-analysis is not without limitations. 
While a previous meta-analysis in patients with exac-
erbations of positive symptoms included 167 placebo-
controlled studies [8], we identified only six placebo-
controlled and 16 active-controlled studies (one study 
had two active treatments and one placebo group) in the 
negative symptom population, and for many comparisons, 
only one study was available. This is not an objection to 
systematically present and review their effect sizes (which 
primarily depend on sample size and not on number of 
studies). This procedure helps to present the data graphi-
cally in a standardized way (effect sizes and their statistical 
significance). In addition, we systematically present which 
studies are available to date. However, it is imaginable 
that some comparisons could show significant effects if 
statistical power was increased. Figure 2,3 and eFigures 7, 
8 show that data on depressive symptoms, positive symp-
toms, and extrapyramidal side effects often were not pre-
sented in the original studies, thus making it difficult to 
evaluate the secondary effects. A systematic reporting of 
these outcomes should be a prerequisite for future stud-
ies on negative symptoms. The major issue is the lack of 
consensus about how to exactly define inclusion criteria 
in such studies [11], so that the criteria in the individual 
studies varied substantially. Moreover, while we addressed 
the predominant/prominent negative symptom distinction 
which had been discussed at a recent conference and is 
important for the FDA and EMA, this distinction is not 
the same as the validated concepts of the deficit syndrome 
[2] and of ‘persistent negative symptoms’ described in
the introduction. These definitions have been developed
scientifically, but rarely applied so far. The “deficit syn-
drome” has only been used in three [34, 35, 41], out of 21
studies and the “persistent negative symptoms” concept
has only been explicitly used in two studies by Buchanan
et al. [32, 64], and a few other studies came close. There-
fore, it was not possible to examine these constructs in
more detail. However, one key aspect of these criteria and
also stressed by the NIMH consensus [65], persistence of
negative symptoms, recommended for at least 6 months
by Buchanan 2007 [7], was considered by only six trials
(see Table 1). Finally, the scores of rating scales to meas-
ure negative symptoms are difficult to interpret clinically.
Equipercentile linking analyses such as one that compared
SANS scores with clinical global impressions of the raters
[66] also would be useful for other scales.
Taken together, our findings showed that the inclusion
criterion ‘predominant negative symptoms’ probably pro-
vides a better safeguard against secondary effects than the 
criterion ‘prominent negative symptoms.’ Amisulpride is the 
best-examined antipsychotic for predominant negative symp-
toms compared to placebo, but this superiority is difficult to 
disentangle from that on depression. A single, though large, 
trial (n = 461) demonstrated a superiority of cariprazine 
compared to risperidone, where effects on depressive symp-
toms, positive symptoms, and extrapyramidal side-effects 
were controlled, [38], but placebo-controlled evidence is 
lacking and the trial was sponsored by cariprazine’s manu-
facturer. Future trials should apply scientifically developed 
definitions such as the deficit syndrome [1] and the persistent 
[7, 67] negative symptoms concept.
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